Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
04 mai 2023 16h30 HE
|
Cellectis Inc.
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s alemtuzumabCellectis...
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
04 mai 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License...
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
02 mai 2023 16h35 HE
|
Cellectis Inc.
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
27 avr. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
27 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
Cardinal Health to provide core distribution capabilities required for U.S. commercialization of CAR T-cell therapiesInnovative Depot Model intended to reduce delivery time by allowing for transit...
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
26 avr. 2023 16h01 HE
|
Autolus Therapeutics plc
LONDON, April 26, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
26 avr. 2023 07h06 HE
|
Autolus Therapeutics plc
- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...
Autolus Therapeutics to Host Virtual Capital Markets Day
25 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a...
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
24 avr. 2023 16h30 HE
|
Cellectis Inc.
Cellectis demonstrated that the addition of alemtuzumab to the lymphodepletion regimen was associated with prolonged lymphodepletion and significantly higher cell expansion and clinical activity NEW...
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
20 avr. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...